On January 6, 2016, Galectin Therapeutics, Inc. (NasdaqCM:GALT) closed the transaction. The company has issued 2,932,408 units for proceeds of received $3,000,000 in funding from five investors in the second tranche. The company has received $5,000,000 in funding.